Urologix Inc. (Nasdaq: ULGX) has hired a new chief financial officer who previously worked as a controller for device firm Angeion Corp.
Brian Smrdel takes over the CFO role from Rebecca Weber, who will stay on as Urologix’s director of finance, according to a statement from the Minneapolis-based company.
Urologix develops devices that treat benign prostatic hyperplasia, or enlarged prostate. The company’s Targis System delivers microwave energy that heats and destroys enlarged prostate tissue and features a cooling mechanism that protects healthy tissue, according to the company.
The company recently reported financial information for its 2010 third quarter, which Warren described as “challenging.” Revenue grew 8 percent to $3.6 million, while Urologix’s net loss narrowed to $597,000. Warren said the company’s financial results were hurt by “physicians’ concern around the future of Medicare Payment rates.”
Comments
Post a comment
No comments yet.
Post a Comment